NanoBio Corporation today announced the appointment of Peter Ulrich, co-founder of TargeGen, to its Board of Directors.
“His insight and expertise will help guide NanoBio as we move our nanoemulsion-based treatments and vaccines towards commercialization and look to develop additional strategic partnerships. Peter will be an asset to our distinguished board.”
Ulrich most recently served as President and CEO of TargeGen, co-founding the company and leading it from inception through exit in a $560 million acquisition by sanofi-aventis. TargeGen developed small molecule kinase inhibitors for oncology, inflammatory disease, eye disease, myeloproliferative disease, leukemia and other hematological disorders.
